» Articles » PMID: 19907424

Increased Cyclic Guanosine Monophosphate Production and Endothelial Nitric Oxide Synthase Level in Mononuclear Cells from Sildenafil Citrate-treated Patients with Erectile Dysfunction

Overview
Journal Int J Impot Res
Date 2009 Nov 13
PMID 19907424
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Mononuclear cells express enzymes involved in the NO/cyclic guanosine monophosphate (cGMP) generating system, as well as PDE5. The objective of the study was to determine the effect of sildenafil citrate administration on the level of proteins involved in the NO/cGMP generating system in mononuclear cells from patients with ED. Twenty-one patients with ED (International Index of Erectile Function-Erectile Function Domain (IIEF-EFD) 17.9+/-0.8) were enrolled and 100 mg sildenafil citrate on-demand was administered during 12 weeks. All patients showed cardiovascular risk factors. After sildenafil citrate administration, IIEF-EFD score was improved (26+/-1.2 P<0.05). In the mononuclear cells, the protein level of endothelial NO synthase (eNOS) was higher after sildenafil citrate treatment. It was accompanied by reduction in the circulating plasma levels of both high-sensitive C-reactive protein and soluble intercellular adhesive molecule-1. The protein level of soluble guanylate cyclase and PDE5 did not change in the mononuclear cells after sildenafil citrate treatment. However, in the mononuclear cells exogenous NO induced a higher cGMP production after 12-weeks sildenafil citrate administration. In conclusion, in mononuclear cells from patients with ED sildenafil citrate administration increased the level of eNOS protein and increased cGMP production in response to NO. Moreover, sildenafil citrate administration reduced the plasma circulating levels of two biomarkers associated with inflammation.

Citing Articles

Phosphodiesterase-5 Expression in Buccal Mucosa of Patients with Erectile Dysfunction One Year after Radical Prostatectomy.

Garcia-Cardoso J, Zamorano-Leon J, Gonzalez-Enguita C, Simon C, Jimenez-Garcia R, Lopez-de-Andres A J Pers Med. 2024; 14(8).

PMID: 39202060 PMC: 11355662. DOI: 10.3390/jpm14080869.


Value of sildenafil treatment for the prevention of vasospasm‑related delayed ischemic neurological deficits and delayed brain infarction following aneurysmal subarachnoid hemorrhage.

Faropoulos K, Tsolaki V, Georgakopoulou V, Trakas I, Tarantinos K, Papalexis P Med Int (Lond). 2023; 3(2):19.

PMID: 37032716 PMC: 10080186. DOI: 10.3892/mi.2023.79.


Screening and identification of critical biomarkers in erectile dysfunction: evidence from bioinformatic analysis.

Hui J, Liu R, Zhang H, He S, Wei A PeerJ. 2020; 8:e8653.

PMID: 32161689 PMC: 7050549. DOI: 10.7717/peerj.8653.


A Phase I proof-of-concept and safety trial of sildenafil to treat cerebral vasospasm following subarachnoid hemorrhage.

Washington C, Derdeyn C, Dhar R, Arias E, Chicoine M, Cross D J Neurosurg. 2015; 124(2):318-27.

PMID: 26314998 PMC: 8157481. DOI: 10.3171/2015.2.JNS142752.


Serum biomarkers in uncontrolled no heart-beating donors may identify kidneys that will never work after transplantation.

Lopez-Farre A, Santos-Sancho J, Modrego J, Segura A, Zamorano-Leon J, Martin L J Nephrol. 2015; 29(1):119-27.

PMID: 25971849 DOI: 10.1007/s40620-015-0203-3.